1.人体腹膜淋巴孔的发育和NO对腹膜淋巴孔的调控,国家自然科学基金NO. 39970381, 2000.1-2002.12
2.内源性NO淋巴孔调控的NO-cGMP/cGMP independent途径与中药治疗腹水机理，国家自然科学基金，NO.30371815, 2004.1-2006.12
3.卵巢淋巴孔发育和调控机理及生殖生理学意义,国家自然科学基金，NO.30470910, 2005.1-2007.12
4.肺结核证候分型血请蛋白质指纹图谱研究,国家自然科学基金NO.81072724, 2011.1-2013.12
5.基于iTRAQ-2DLC-MS/MS的肺痨证候标志性血请蛋白质的筛选和鉴定,国家自然科学基金No.81273882; 2013.1—2016.12
6.肺结核中西医结合治疗方案的研究,国家“十一五”重大科技专项2008ZX10503, 2008.1—2011.12
7.基于转化医学的肺结核证候生物信息研究,国家“十二五”重大科技专项2012ZX10005001-006，2012.1—2015.12
8.滋阴降火方药治疗阴虚“上火”的作用机制研究, 973项目2014CB543002，2014.1--2018.12
9.耐多药肺结核病中医证候血清蛋白质标志物的筛选、鉴定及功能研究，国家自然科学基金NO. 81573709, 2016.1--2019.12
10.活动性肺结核病新分子标志物lncRNA/T-UCRs的筛选、鉴定及功能研究,国家自然科学基金NO.8177080550，2018.1—2021.12
(corresponding author)
1.Chen JX, Han YS, Zhang SQ, Li ZB, Chen J, Yi WJ, Huang H, Jiang TT,Li JC*. Novel therapeutic evaluation biomarkers of lipid metabolism targets in uncomplicated pulmonary tuberculosis patients. Signal Transduction and Targeted Therapy 2021 Jan 18;6(1):22.
2.Zhi-Bin Li, Jun Liu(#), Shan-Qiang Zhang(#), Yi Yu, Hong-Feng Liang, Qi-Qi Lu, Jing Chen, Yu-Shuai Han, Fan Zhang,Ji-Cheng Li(*). Novel potential metabolic biomarker panel for early detection of severe COVID-19 using full-spectrum metabolome and whole-transcriptome analyses. Signal Transduct Target Ther. 2022;7(1):129.
3.Qiqi Lu, Jun Liu, Yi Yu, Hong-Feng Liang, Shan-Qiang Zhang, Zhi-Bin Li, Jia-Xi Chen, Qiu-Gui Xu, Ji-Cheng Li(*). ALB, HP, OAF and RBP4 as novel protein biomarkers for identifying cured patients with pulmonary tuberculosis by DIA. Clin Chim Acta. 2022 Aug 12;535:82-91.
4.Jun Liu, Zhi-Bin Li, Qi-Qi Lu, Yi Yu, Shan-Qiang Zhang, Pei-Feng Ke, Fan Zhang, Ji-Cheng Li(*).Metabolite profile of COVID-19 revealed by UPLC-MS/MS-based widely targeted metabolomics. Front Immunol, 2022;13:894170.
5.Jun Liu, Liangqiu Tang, Qiqi Lu, Yi Yu, Qiu-Gui X, Shanqiang Zhang, Yun-Xian Chen, Wen-Jie Dai, Ji-Cheng Li(*). Plasma Quantitative Lipid Profiles: Identification of CarnitineC18:1-OH, CarnitineC18:2-OH and FFA (20:1) as Novel Biomarkers for Pre-warning and Prognosis in Acute Myocardial Infarction. Front Cardiovasc Med. 2022 Apr 11;9:848840.
6.Shanqiang Zhang, Su-Ming Pan, Shu-Zhen Lai, Hui-Jing Situ, Jun Liu, Wen-Jie Dai, Si-Xian Liang, Li-Qing Zhou, Qiqi Lu, Pei-Feng Ke, Fan Zhang, Hai-Bin Chen, Ji-Cheng Li(*). Novel Plasma Proteomic Biomarkers for Early Identification of Induction Chemotherapy Beneficiaries in Locoregionally Advanced Nasopharyngeal Carcinoma. Front Oncol, 2022 Jun 30;12:889516.
7.Jun Liu, Shanqiang Zhang, Wenjie Dai, ChongweiXie, Ji-Cheng Li*. A comprehensive prognostic and immune analysis of SLC41A3 in pan-cancer [J]. Frontiers in Oncology. 2021 Jan 14;10:586414.
8.Shan-Qiang Zhang, Su-Ming Pan, Si-Xian Liang, Yu-Shuai Han, Hai-Bin Chen, Ji-Cheng Li*. Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high throughput omics [J]. Int J Oncol. 2021 Apr;58(4):9.
9.Li ZB, Han YS, Wei LL, Shi LY, Yi WJ, Chen J, Huang H, Jiang TT, Li JC*.Screening and identification of plasma lncRNAs uc.48+ and NR_105053 as potentialnovel biomarkers for cured pulmonary tuberculosis. Int J Infect Dis. 2020 Mar;92:141-150.
10.Huihui Tu, Su Yang, Tingting Jiang, Liliang Wei, Liying Shi, Changming Liu, Chong Wang, Huai Huang, Yuting Hu, Zhongliang Chen, Jing Chen, Zhongjie Li &Jicheng Li * ,Elevated pulmonary tuberculosis biomarker miR-423-5p plays critical role in the occurrence of active TB by inhibiting autophagosome-lysosome fusion, Emerging Microbes & Infections, 2019,8:1, 448-460
1.李继承、刘姬艳.含有肺结核血清特征蛋白的样品及其制备方法。国家发明专利,专利号201210133113X
2.李继承、张星.一种检测活动性肺结核病的试剂盒。国家发明专利，专利号201210338287X
3.李继承、江婷婷.用于肺结核证候特征蛋白质检测的试剂盒及其应用。国家发明专利，专利号2012104997119
4.李继承、张星.一种活动性肺结核病特异的血清miRNAs的制备方法。国家发明专利，专利号2012101719198
5.李继承、王冲.肺结核疗效评价试剂盒及其应用。国家发明专利，专利号2015102189544
6.李继承、江婷婷、陈静.肺结核病强化治疗后疗效评价和预后评估试剂盒及其用途。国家发明专利，专利号2017113975732
7.李继承、陈静.一种检测阴虚上火体质中血清特异蛋白的试剂盒及其应用。国家发明专利，专利号：2017113781366
8.李继承、屠慧惠.hsa-miRNA-423-5p和hsa-miRNA-423-5p抑制剂的用途。国家发明专利，专利号：2018105522716
9.李继承、刘昌铭.一种用于检测阴虚上火体质血清特异性miRNA的试剂盒及其应用。国家发明专利，专利号：2017113781402
10.李继承、李志斌.一种基于血浆lncRNA组合物的肺结核疗效评价试剂盒及其用途。国家发明专利，专利号：2019102794624
